Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care

Recruiting now

Conditions studied: Hepatic Fibrosis

In brief

Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4). Given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis

Key facts

Study ID

NCT06119997

Run by

University Hospital, Grenoble

People needed

500

Starts

2025-06-26

Expected to finish

2028-07-30

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients between 18 and 70 years of age
• FIB-4 2.67
• Patients covered by Health Insurance System

You may not qualify if…

• Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist
• Conditions associated with high risk false-positive FIB-4: ASAT or ALAT > 300 IU/L, platelets <50 G/L or >500 G/L.
• Patient refusing to participate
• Subjects under guardianship or deprived of liberty

Where it is running

• CHU Grenoble Alpes — Grenoble, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.